Loading...
•
Mar 31, 2022
DexCom Q1 2022 Earnings Report
Reported revenue growth of 25% and secured CE Mark for Dexcom G7 CGM System.
Key Takeaways
DexCom, Inc. reported a 25% increase in worldwide revenue, reaching $628.8 million, driven by volume growth and new customer additions. The company secured CE Mark for the Dexcom G7 CGM System and advanced access to Dexcom CGM for people with diabetes.
Revenue grew 25% versus the same quarter of the prior year to $628.8 million.
U.S. revenue growth of 18% and international revenue growth of 43%.
Secured CE Mark for the Dexcom G7 CGM System and initiated a limited launch of G7 in Europe.
GAAP net income was $97.3 million, or $0.93 per diluted share.
DexCom
DexCom
DexCom Revenue by Segment
DexCom Revenue by Geographic Location
Revenue by Segment
Sensor and other Revenue
CapyFin.comHardware Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
The company is reiterating guidance for fiscal year 2022 revenue, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin at the following levels:
Positive Outlook
- Revenue of approximately $2.82 - 2.94 billion (15-20% growth)
- Non-GAAP Gross Profit Margin of approximately 65%
- Non-GAAP Operating Margin of approximately 16%
- Adjusted EBITDA Margin of approximately 25%
Revenue & Expenses
Visualization of income flow from segment revenue to net income